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Abstract
The cross-talk between beta cells and endothelium plays a key role in islet physiopathology and in the revascularization
process after islet transplantation. However, the molecular mechanisms involved in this cross-talk are not fully elucidated.
Extracellular vesicles (EVs) are secreted membrane nanoparticles involved in inter-cellular communication through the
transfer of proteins and nucleic acids. The aims of this study were: 1) isolation and characterization of EVs from human islets;
2) evaluation of the pro-angiogenic effect of islet-derived EVs on human islet endothelial cells (IECs). EVs were isolated by
ultracentrifugation from conditioned medium of human islets and characterized by nanotrack analysis (Nanosight), FACS,
western blot, bioanalyzer, mRNA/microRNA RT-PCR array. On IECs, we evaluated EV-induced insulin mRNA transfer,
proliferation, resistance to apoptosis, in vitro angiogenesis, migration, gene and protein profiling. EVs sized 236654 nm,
expressed different surface molecules and islet-specific proteins (insulin, C-peptide, GLP1R) and carried several mRNAs
(VEGFa, eNOS) and microRNAs (miR-27b, miR-126, miR-130 and miR-296) involved in beta cell function, insulin secretion and
angiogenesis. Purified EVs were internalized into IECs inducing insulin mRNA expression, protection from apoptosis and
enhancement of angiogenesis. Human islets release biologically active EVs able to shuttle specific mRNAs and microRNAs
(miRNAs) into target endothelial cells. These results suggest a putative role for islet-derived EVs in beta cell-endothelium
cross-talk and in the neoangiogenesis process which is critical for engraftment of transplanted islets.
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Introduction
The cross-talk between beta cells and endothelial cells
represents a key mechanism in the physiopathology of
pancreatic islets [1,2]. Islet endothelial cells (IECs) release
molecules such as hepatocyte growth factor involved in beta cell
proliferation and differentiation [3]. On the other hand, beta
cells secrete pro-angiogenic factors that are able to promote islet
vascularization [4–6]. The maintenance of endothelial integrity
is relevant not only in native islets but also in islet
transplantation, where lack of revascularization is a main cause
of loss of graft function [7,8].
It has been demonstrated that conditioned medium derived
from cultured rat islets induces liver and islet-derived endothelial
cell proliferation and migration in vitro [9], suggesting the
presence of paracrine pro-angiogenic factors. Extracellular
vesicles (EVs) represent a newly discovered mechanism of cell-
to-cell communication. EVs are released by a membrane sorting
process from different types of activated cells influencing the
behaviour of surrounding target cells through the transfer of
bioactive lipids, proteins, receptors and genetic information [10–
12]. We recently demonstrated that EVs derived from
endothelial progenitor cells (EPCs) activate an angiogenic
program in quiescent endothelial cells through the horizontal
transfer of RNAs [13]. In addition, EPC-derived EVs enhance
neo-angiogenesis in transplanted pancreatic islets through
mRNA and microRNA transfer [14]. Other types of fully
differentiated cells have been shown to produce biologically
active EVs [15–17]. However, the release of EVs from human
pancreatic islets has not been investigated yet. The aim of the
present study was to isolate EVs released from human islets and
to evaluate their potential role in beta cell-endothelium cross-
talk and in islet angiogenesis.
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Materials and Methods
Isolation and characterization of islets and islet-derived
EVs
The use of human specimens (supernatant of cultured islets or
islets discarded from clinical use) was approved by Institutional
Review Board. Islet-free supernatants were obtained from freshly
purified human islet preparations (n = 10) from Diabetes Research
Institute (HSR-DRI), San Raffaele Scientific Institute, Milan,
Italy. Islets were isolated and purified according to the automated
method described by Ricordi, with local modifications [18].
Briefly, the pancreatic duct was cannulated with 14–20 G catheter
and distended by intraductal infusion of a cold collagenase solution
(Collagenase NB1 Premium Grade, Serva, Heidelberg, Germany).
After digestion at 37uC in a modified Ricordi chamber, islets were
purified on a Cobe 2991 (TerumoBCT, Lakewood, CO, USA)
using a continuous HBSS-Ficoll (Biochrom, Berlin, Germany)
gradient. Purified islet fractions were cultured in Final Wash
(Mediatech Cellgro, VA, USA) plus 1% Pen/Strep, 1% Glutamine
(Lonza, Basel, Switzerland), counted and their numbers expressed
as number of islets normalized to a 150-mm diameter (IEQ). Final
islet preparations were cultured at a density of 10006150 IEQ/
ml.
Human islet preparations were selected for purity (.70%) and
viability (.70%) for EV isolation by Dithizone (Sigma-Aldrich, St.
Louis, MO) and Fluorescein Diacetate/Propidium Iodide (FDA/
PI; (Sigma-Aldrich, St. Louis, MO) dye analysis.
Fluorescein Diacetate/Propidium Iodide (FDA/PI)
Supernatants (100 ml each) were collected for 24 hrs, submitted
to 3 centrifugations at 4,0006g for 20 minutes (4 K fraction) to
eliminate islet and cell debris. The islet-free supernatants were
centrifuged at 100,0006g (Beckman Coulter Optima l-90K;
Fullerton, CA) for 1 hr at 4uC. EVs were washed in serum-free
medium 199 (Sigma-Aldrich) containing 25 mM HEPES and
submitted to a second ultracentrifugation at 100,0006g for 1 hr at
4uC and resuspended in 200 ml of serum-free medium 199 (Sigma-
Aldrich). The protein content of EVs was quantified by Bradford
method (Biorad, Hercules, CA, USA) and EVs were stored at 2
80uC. In selected experiments, islet-free supernatants were
subjected to serial centrifugation: the first one at 10,0006g
(10 K fraction) and the second one at 100,0006g (100 K fraction)
to evaluate the presence of apoptotic bodies and the biological
activity of different EV fractions by BrdU-based assay (see below).
To trace EVs for FACS analysis, after isolation EVs were labeled
with red fluorescence aliphatic chromophore intercalating into
lipid bilayers PKH26 (Sigma-Aldrich) or with DNA intercalating
dye, that differentially stains double-stranded and single-stranded
nucleic acids, acridine orange solution (Sigma-Aldrich). In selected
experiments, EVs were treated with 1 U/ml RNase (Ambion Inc.,
Austin, TX) as previously described [13,14]. The reaction was
stopped by addition of 10 U/ml RNAse inhibitor (Ambion) and
EVs were washed by ultracentrifugation.
Nanosight analysis
EVs were analysed by Nanosight LM10 system (Nanosight Ltd.,
Amesbury, UK). Briefly, EV preparations were diluted (1:100) in
sterile saline solution 0.9% and analysed by NanoSight LM10
equipped with the Nanoparticle Analysis System & NTA 1.4
Analytical Software [14,19].
Isolation and characterization of IECs
Freshly purified human islet preparations (n = 5), discarded
from transplant use for insufficient islet mass, were cultured, after
approval by the local ethical committee, on tissue culture treated
flasks in CMRL1066 with 10% FBS (Life Technologies, Carlsbad,
CA). After 7 days of culture, cells derived from the outgrowth were
transfected with pBR322 plasmid vector containing SV40-T large
antigen gene and clones sorted for CD31 and characterized as
previously described [20].
GUAVA FACS analysis
FACS analysis was performed with GUAVA (GUAVA Easy-
Cyte, Millipore) that allows direct detection of nanoparticles with
about 200 nm [21], using APC-, PE- or FITC-conjugated
antibodies directed to a4, a6, b1(CD29) integrins, HLA I, HLA
II, CD44, CD31, ICAM-1 (Beckton Dickinson, Franklin Lakes,
NJ), GLP1R and glucagon (Santa Cruz, Dallas, TX). FITC or PE
mouse nonimmune isotypic IgG (Beckton Dickinson, Franklin
Lakes, NJ) was used as control. In particular, EVs were incubated
with each antibody, or isotype control antibody, with or without
permeabilization solution, for 1 hour at 4uC and after appropriate
washing and centrifugation, analysed by FACS. By cytofluori-
metric analysis EVs were detected mainly below the forward
scatter signal corresponding to 1 mm beads (data not shown).
To evaluate EV internalization, IECs were incubated with
different doses of PKH26-labelled EVs (0, 5, 10, 25, 50, 100 mg/
ml) for different time points (0, 3, 6, 12, 24 hours) in serum free
medium and then, after appropriate washing, analysed by FACS.
In selected experiments, blocking antibodies or peptides
directed to different integrins (a6, a4, b1(CD29) and ICAM1
(Millipore, Billerica, MA) or soluble hyaluronic acid (HA; Sigma,
St. Louis, MO) were used. Briefly, EVs were pre-incubated for
1 hr at 4uC with 1 mg/ml of blocking antibodies or 5 mg/ml of
soluble HA and then, after appropriate washing and centrifuga-
tion, EVs were incubated with IECs for 30 minutes in serum free
medium. After incubation with EVs, IECs were washed and
analyzed by FACS.
RNA extraction and Bioanalyzer analysis
Total RNA from islets and from islet EVs was extracted by
Mirvana kit (Ambion Inc, Austin, TX) according to manufactur-
er’s instructions. Analysis of RNAs contained in islets and in
RNase-treated and untreated islet EVs was assessed by Agilent
2100 Bioanalyzer (Agilent Tech, Inc., Santa Clara, CA) using the
Figure 1. Characterization of human islet-derived EVs. A) Nanosight analysis of 10 k and 100 k fraction EVs. In Nanosight analysis, curve 1
describes the relationship between particle number distribution (left Y axis) and particle size (X axis); curve 2 describes the correlation between
cumulative percentage distribution of particles (percentile in right Y axis) and particle size (X axis). B) GUAVA FACS analysis of 10 k and 100 k fraction
EVs stained with acridine orange and evaluated for red fluorescence (RNA) or for green fluorescence (DNA). C) GUAVA FACS analysis of surface
molecules (and glucagon) expressed by 100 k total EVs. Dark grey filled curves represent the percentage of positive cells in respect to control (light
grey curves). Kolmogorov-Smirnov statistical analysis was performed (p,0.05). D) Western blot analysis of human islets and human islet-derived EVs
for beta cell, endothelial cell and EV markers. Results are expressed as ratio of different protein levels between EVs and Islets normalized for beta actin
ratio. Actin was used as experimental control. E) Bioanalyzer RNA profiling of human islets and islet-derived EVs for total RNAs (upper panels) and
small RNAs (lower panels). F) Analysis of microRNAs (microRNA array) present in human islets and islet-derived EVs (left circle: islets; right circle: islet-
derived EVs). Three different EV preparations were analyzed with similar results.
doi:10.1371/journal.pone.0102521.g001
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eukaryotic total RNA 6000 Nano kit and small RNA kit (Agilent
Tech.).
DNA extraction and Agarose gel electrophoresis analysis
Total DNA from 10 k and 100 k fraction EVs was extracted by
all-in-one purification kit (Norgen biotek corp., Thorold, Canada)
according to manufacturer’s instructions. DNA contained in islet
EVs was subjected to 1% agarose gel electrophoresis containing
ethidium bromide and analysed under ultraviolet (UV) light.
RT-PCR array analysis of islet EVs and IECs
Human diabetes (PAHS-023: European Bioinformatics Institute
E-MEXP-3695; www.ebi.ac.uk) and human angiogenesis (PAHS-
024: European Bioinformatics Institute E-MEXP-3693; www.ebi.
ac.uk) RT2 profiler PCR arrays (SABiosciences, Frederick, MD,
USA) were used to characterize respectively the gene expression
profiles of human islet-derived EVs or IECs stimulated or not with
50 mg/ml of islet EVs for 12 and 24 hrs.
Briefly, according to manufacturer’s instructions, RNA extract-
ed from islet EVs and IECs was treated with gDNA elimination
buffer, to degrade DNA contamination, and then reverse-
transcripted by using RT2 first strand kits. RT products were
loaded into 96 well array and Real Time RT-PCR amplification
was performed by using the Bio-Rad iCycler Real Time PCR
System. Data analysis was performed using RT2 Profiler PCR
Array Data Analysis tool provided by manufacturer (SA-
Bioscience) and the expression levels of each gene were normalized
for housekeeping genes according to manufacturer’s instruction.
MicroRNA analysis in islet EVs
MicroRNA (miRNA) analysis was performed by TaqMan
Human MicroRNA A card (Life Technologies, Carlsbad, CA) in
accordance to manufacturer’s instructions (European Bioinfor-
matics Institute E-MEXP-3691; www.ebi.ac.uk). Briefly, RNAs
isolated from islets and islet EVs were reverse-transcripted by
using Megaplex RT kit containing RT primers, allowing reverse
transcription of all 365 miRNA targets in one RT reaction. The
RT reaction products was submitted to a preamplification
reaction, consisting of 12 cycles reaction, to improve signal for
small quantity of RNA as indicated in user’s guide. Finally,
preamplification reaction products were simply loaded into one of
the eight filling ports on the TaqMan Array and then Real Time
RT-PCR Amplification was performed by using the Applied
Biosystem 7900 HT Fast Real Time PCR System. Data Analysis
was performed by a bioinformatic software (SDS manager) to
analyze and find cycle amplification differences among miRNAs
and to normalize all miRNAs data with snoRNA data (endoge-
nous control) present in the same array in accordance to
manufacturer’s instructions.
Western blot analysis of islets, islet EVs and IECs
Islets, islet-derived EVs or IECs stimulated or not with 50 mg/
ml of islet EVs or RNase pre-treated islet EVs at different time
points were lysed at 4uC for 1 hour in a lysis buffer (50 mM Tris-
HCl, pH8.3, containing 1% Triton X-100, 1 mM PMSF, 10 mg/
mL leupeptin and 100 U/mL aprotinin) then quantified using
Bradford method by Nanodrop 1000 (Nanodrop, Wilmington,
DE, USA) and analyzed by western blot. Briefly, 30 mg of sample
lysates were subjected to 4% to 15% gradient sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions and electroblotted onto nitrocellulose mem-
brane filters. The following primary antibodies were used: human
insulin, GLUT 2, PDX 1, AGO2, Angiopoietin-1, CD63, VEGF-T
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A, VEGFR1, VEGFR2, AKT, p-AKT, eNOS, p-eNOS, ERK, p-
ERK, BAD, Bcl-2, Thrombospondin-1, actin (Santa Cruz
Biotech, Santa Cruz, CA) and human C-peptide (Abcam,
Cambridge, MA). After incubation for 12 hours at 4uC with
primary antibodies, nitrocellulose membrane filters were washed
with PBS 10% BSA 0.5% tween 20 and then incubated with
specific HRP-conjugated secondary antibodies for 1 hour at room
temperature. After washing step, nitrocellulose membrane filters
were incubated with ECL western blot detection system (GE
healthcare, Amersham, Buckinghamshire, UK) for 10 minutes and
images were captured by ChemiDoc XRS system (Biorad). Images
of nitrocellulose membrane filters were analyzed by ImageJ
software (Image processing and analysis in Jave) to quantify size
and strength of protein bands.
In vitro assays on IECs
IEC proliferation was studied by 5-bromo-2-deoxyuridine
(BrdU) (Roche Diagnostics, Mannheim, Germany) incorporation
in cells stimulated or not with different doses of islet EVs and with
RNase pre-treated EVs (50 mg/ml) for 12 hrs.
Briefly, IECs were cultured on 24-well and stimulated or not
with different doses of islet EVs (1, 5, 10, 25, 50 mg/ml) and with
RNase pre-treated EVs (50 mg/ml) for 12 hours in RPMI without
serum in presence of 10 mM BrdU (Roche Diagnostics, Mann-
heim, Germany). After incubation, cells were washed and fixed
with fixing solution, treated with nucleases to digest cellular DNA
and then incubated with anti-BrdU-POD antibody. Finally,
peroxidase substrate ABTS was added and peroxidase catalysed
the cleavage of ABTS producing a colored reaction product
directly proportional to the amount of BrdU integrated into cell
DNA. In addition, different fractions of EVs obtained by serial
ultracentrifugation were also tested and in selected experiments,
EVs (50 mg/ml) were pre-treated with blocking antibodies direct to
ICAM-1 or with HA, as described above. The absorption values
were determined at 405 nm wave length by Biorad spectropho-
tometer.
IEC apoptosis was evaluated by TUNEL assay (ApopTag from
Oncor, Gaithersburg, MD) on cells stimulated or not with
different doses of EVs and with RNase pre-treated EVs (50 mg/
ml) for 48 hrs. Briefly, IECs were subjected to TUNEL assay
(terminal deoxynucleotidyltransferase (TdT)-mediated dUTP nick
end labeling) (ApopTag, Oncor, Gaithersburg, MD) after starving
for 12 hrs without FCS. IECs were stimulated or not with different
doses of islet EVs (1, 5, 10, 25, 50 mg/ml) and with RNase pre-
treated EVs (50 mg/ml) for 48 hours. Cells were fixed in 1%
paraformaldehyde, post-fixed in pre-cooled ethanol-acetic acid
2:1, incubated with TdT enzyme in a humidified chamber at 37uC
for 1 hr and counterstained with antidigoxigenin-FITC antibody
and with propidium iodide (1 mg/mL). In selected experiments,
EVs (50 mg/ml) were pre-treated with blocking antibody direct to
ICAM-1 or HA, as described above. Samples were analyzed under
a fluorescence microscope and green-stained apoptotic cells were
counted in 10 non-consecutive microscopic fields.
IEC migration was evaluated by 106 phase-contrast objective
under the above-mentioned Nikon system. Briefly, IECs were
plated and rested for 12 hrs with RPMI without serum and
subsequently stimulated or not with 50 mg/ml of Islet EVs, with
RNase-pretreated islet EV or cultured in endothelial growth factor
enriched medium (EBM medium, Lonza) for 6 hours. The net
migratory speed (velocity straight line) was calculated by the
MicroImage software based on the straight line distance between
the starting and ending points divided by the time of observation.
Migration of at least 30 cells for each experimental point was
analysed [20].
Angiogenesis in vitro was evaluated as capillary-like structures
formed by IECs (56104 cells/well) seeded on growth factor–
reduced Matrigel (Beckton Dickinson, Franklin Lakes, NJ) in
RPMI without serum. Briefly, IECs were stimulated or not with
50 mg/ml of EVs, RNase pre-treated EVs or cultured in
endothelial growth factor enriched medium (EBM medium from
Lonza, Basel, Switzerland) for 12 and 24 hrs. Cells were observed
under a Nikon-inverted microscope, using a 506magnification,
and experimental results were recorded after 12 and 24 hours of
incubation with different stimuli at 37uC. Results were given as
average number of capillary-like structures/field (magnifica-
tion650) 6 SD of three different experiments.
Quantitative Real Time PCR
Quantitative real-time PCR was performed on total RNA
extracted from islet EVs and IECs to confirm gene array data.
Moreover, for selected experiments, the specific primers for
human insulin were: F1-AAGAGGCCATCAAGCAGATCA and
R1-CAGGAGGCGCATCCACA. First-strand cDNA was pro-
duced from total RNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA). Briefly,
200 to 400 ng mRNA, 2 ml RT buffer, 0.8 ml dNTP mixture, 2 ml
RT random primers, 1 ml MultiScribe reverse transcriptase, and
4.2 ml nuclease-free water were used for each cDNA synthesis.
After the reverse transcription, cDNA was stored at –20uC. 20 ml
of RT-PCR mix, containing 16SYBR GREEN PCR Master Mix
(Applied Biosystems), 100 nM of each primer, and 0 ml, 1 ml, and
2 ml of MV cDNA, were assembled using a 48-well StepOne Real
Time System (Applied Biosystems). Negative cDNA controls (no
cDNA) were cycled in parallel with each run. Results are
expressed as normalized values of mRNA mean differences
(2‘2DDCt 6 SD).
Quantitative real-time PCR for miRNAs was performed on
total RNA extracted from IECs treated or not with islet-derived
EVs and actinomycin D (Sigma). Briefly, IECs were treated with
actinomycin D (5 mg/ml) for 30 minutes, in order to block RNA
transcription, then washed and treated or not with EVs (50 mg/ml)
at different time points. 200 ng of RNA was reverse-transcribed by
the miScript Reverse Transcription Kit. cDNA was then used to
detect and quantify miRNAs of interest by qRT-PCR using the
miScript SYBR Green PCR Kit (Qiagen, Valencia, CA, USA). All
samples were run in triplicate using 5 ng of cDNA for each
Figure 2. Internalization of islet-derived EVs into IECs and transfer of insulin mRNA and microRNAs. A–B) Quantification by GUAVA
FACS of EV internalization in IECs at different doses (range 5–100 mg/ml) or at different time points with a single EV dose (50 mg/ml). C) Quantification
by GUAVA FACS of internalization of EVs pre-labelled with PKH26 in presence or absence of hyaluronic acid or of blocking monoclonal antibodies
directed to ICAM-1, integrins (alpha 4, alpha 6, beta 1) (*p,0.05 EVs+blocking monoclonal antibodies versus EVs alone). D) RT-PCR quantification of
insulin mRNA in IECs treated with EVs at different time points. Results are expressed as normalized values of mRNA mean differences (2‘2DDCt 6 SD)
between each sample compared to IECs stimulated with EVs for 3 hrs (adopted as RQ=1), (*p,0.05 EVs at 3 and 6 hrs vs. vehicle alone or EVs at 12
or 24 hrs). E) RT-PCR quantification of miR-375, miR-200c and miR-21 in IECs treated with actinomycin D (5 mg/ml) and EVs at different time points.
Results are expressed as normalized values of miRNA mean differences (2‘2DDCt 6 SD) between each sample compared to IECs treated only with
actinomycin D (*p,0.05 EVs at 3 hrs or 6 hrs vs. vehicle alone). Three different experiments were performed with similar results. For FACS
experiments, Kolmogorov-Smirnov statistical analysis was performed.
doi:10.1371/journal.pone.0102521.g002
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Figure 3. Pro-angiogenic and anti-apoptotic effects of EVs on IECs. A) BrdU proliferation assay of IECs incubated for 12 hrs with different
doses of EVs or with RNAse pre-treated EVs (*p,0.05 EVs vs. vehicle alone or RNase EVs). B) Apoptosis (TUNEL assay) of IECs incubated for 48 hrs with
different doses of EVs or with RNAse pre-treated EVs (*p,0.05 EVs vs. vehicle alone or RNase pre-treated EVs). C) BrdU proliferation assay of IECs
incubated for 12 hrs with EVs (50 mg/ml) pre-treated or not with a blocking antibody directed to ICAM-1 or with HA (*p,0.05 EVs+blocking
monoclonal antibody or HA versus EVs alone). D) Apoptosis (TUNEL assay) of IECs incubated for 48 hrs with EVs (50 mg/ml) pre-treated or not with a
blocking antibody directed to ICAM-1 or with HA (*p,0.05 EVs+blocking monoclonal antibody or HA versus EVs alone). E) Time-lapse
videomicroscopy analysis of 6 hrs IEC migration induced by EVs (50 mg/ml), EVs pre-treated with 1 U/ml RNase or by medium enriched for endothelial
growth factors (EndoGF medium) (*p,0.05 EVs or EndoGF medium vs. vehicle alone; #p,0.05 RNase EVs vs. EVs). F–G) count and representative
micrographs of in vitro formation of capillary-like structures by IECs seeded on Matrigel-coated surfaces in the presence of vehicle alone, EVs (50 mg/
ml), RNase pre-treated EVs or medium enriched for endothelial growth factors (EndoGF medium) for 12 hrs (white columns) or 24 hrs (black columns)
(*p,0.05 EVs or EndoGF medium vs. vehicle alone; #p,0.05 RNase EVs vs. EVs).
doi:10.1371/journal.pone.0102521.g003
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reaction. miRNAs specific primers to hsa-miR-375, hsa-miR-200c
and has-miR-21 were used in separate reactions. The snoRNAs,
RNU48 and RNU44 were used as positive controls. qRT-PCR
was performed using a 48- well StepOne Real Time System
(Applied Biosystems). Negative cDNA controls (no cDNA) were
cycled in parallel with each run. Results are expressed as
normalized values of miRNA mean differences (2‘2DDCt 6 SD).
Statistical analysis
All data of different experimental procedures are expressed as
average 6 SD. Statistical analysis was performed by Student’s t-
test or ANOVA with Newmann-Keuls or Dunnet’s multicompar-
ison test where appropriated.
Figure 4. Representative gene array analysis for angiogenesis-related genes of IECs cultured in different experimental conditions.
A–B) Results are expressed as fold-variation of pro-angiogenic and anti-angiogenic genes of IECs cultured for 12 hrs (gray columns) or 24 hrs (black
columns) with EVs or with vehicle alone. Samples were normalized for signals generated by housekeeping genes (Actin, GAPDH). Three independent
experiments were performed with similar results. Gene table: AKT1, Angipoietin1, CXCL 1, Ephrin A3, Fibroblast Growth Factor Receptor 3, Vascular
Endothelial Growth Factor Receptor 1, HAND 2, Jagged 1, Leptin, MDK, Neuropilin 2, TIE 2, Angiopoietin 2, BAI 1, Endostatin, Tumstatin, CXCL 10,
Notch 4, Thrombospondin 1, Tissue Inhibitor of metallo proteinases 1 and 2.
doi:10.1371/journal.pone.0102521.g004
Figure 5. Representative western blot analysis and relative densitometric quantification of molecules involved in angiogenesis and
apoptosis expressed by IECs after incubation with EVs at different time points. Results are expressed as ratio of different proteins (VEGFR1,
VEGFR2, VEGF-A, Angiopoietin1, Thrombospondin1, BAD and Bcl2) in respect to beta actin (control). Three different experiments were performed and
data are expressed as mean 6 SD. (*p,0.05 EVs at different time points vs. vehicle alone).
doi:10.1371/journal.pone.0102521.g005
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Results
Characterization of islet-derived EVs
By Nanosight analysis, both 10 k and 100 k RCF (relative
centrifugal force) EVs showed a similar size (256689 nm and
236654 nm, respectively), indicating that islet-derived EVs were
only composed by small vesicles (Figure 1A). Larger vesicles,
apoptotic bodies and cell debris were removed by 4000 g
centrifugation. This was confirmed by GUAVA FACS analysis,
showing that the 4 k fraction contained 10.362.7% of particles
with a size .1 mm whereas large vesicles were absent in 10 k and
100 k fractions (not shown). The absence of apoptotic bodies in
both 10 k and 100 k EV fractions was indicated by absence of
DNA assessed by acridine orange test (GUAVA FACS) (Figure 1B).
DNA was not detected in 10 k and 100 k EV fractions also after
DNA extraction and analysis by agarose gel electrophoresis (not
shown). We found that islets released 1.16260.22 N 10‘6 EVs/
IEQ. Moreover, 1 mg of EVs corresponded to 64.6616.2 N 10‘6
EVs. GUAVA FACS analysis also revealed the presence on EV
surface of several molecules such as alpha6- and beta1-integrin,
CD44, ICAM-1, CD31 and GLP1R in both 10 k and 100 k
fractions (Figure 1C). In EVs, glucagon was detected at very low
level (Figure 1C). Moreover, the potential proliferative effect of the
different EV subpopulations (10 k and 100 k RCF) was evaluated
by BrdU assay on IECs and both subpopulations showed similar
proliferative effect (not shown). Since the yield of vesicles was 100
times more in total 100 k fraction than in the 10 k fraction we
performed further experiments with total 100 k fraction of EVs.
Staining with PKH26 which labelled membrane phospholipids
allowed detection of EVs by GUAVA FACS analysis indicating
that particles detected were not protein aggregates. Western blot
analysis of lysates derived from EVs showed the presence of
insulin, C-peptide, the typical exosome marker CD63, the effector
component of miRNA-mediated silencing complex Argonaute-2
(AGO-2) and molecules involved in cell proliferation such as
AKT/p-AKT (Figure 1D). Furthermore, RNA extracted from
islets and islet-derived EVs was submitted to Bioanalyzer profiling.
In comparison to whole islets, EVs did not express the ribosomal
RNA subunits 18S and 28S, whereas they were particularly
enriched in small RNAs with a length of about 20–25 nucleotides,
presumably miRNAs (Figure 1E). The comparative analysis of
small RNAs showed enrichment in EVs (3563.61%) in compar-
ison to whole islets (1762.82%). Moreover, EVs also contained
RNAs of different lengths included between 40 and 400–500
nucleotides (Figure 1E). To further investigate the RNA content of
islet-derived EVs, RT-PCR array for transcripts relevant to islet
physiology was performed (table 1). EVs contained transcripts
involved in different processes such as endothelial cell activation
and angiogenesis (endothelial nitric oxide synthase, eNOS vascular
endothelial growth factor alpha VEGFa), insulin production and
signal transduction (PDX-1, insulin, insulin receptor, insulin
receptor substrate2, PI3K subunits, AKT2), glycogen/lipid/
protein synthesis (glucose transporter4, glucose-6-phosphatase,
glycogen synthase kinase3) and peroxisome proliferator-activated
receptor pathway (PPARA, PPARG, PPARGC1A, PPARGC1B)
(Table 1). In particular, EVs were enriched for insulin mRNA and
contained lower levels of glucagon and eNOS, suggesting their
main beta-cell origin (Table 1). The presence in EVs of genes
randomly chosen from those detected by array was confirmed by
quantitative RT-PCR (not shown). We also performed TaqMan
Array MicroRNA Card A, confirming the presence of several
miRNAs within EVs as suggested by Bioanalyzer profiling.
Indeed, we found 208 miRNAs within EVs (Figure 1F): 200
miRNAs were shared between islets and islet-derived EVs,
whereas 8 miRNAs were specifically concentrated in EVs
(Figure 1F and Table 2). By contrast, 41 miRNAs detected in
islets were not present in EVs (Figure 1F). In particular, some
shared miRNAs were enriched in EVs while other shared miRNAs
were enriched in islets, suggesting a specific miRNA sorting
mechanism during EV formation (Table 2). We found in EVs the
presence of the islet specific miRNA miR-375 and of the so called
‘‘angiomiRs’’ which are known to promote angiogenesis (miR-126
and miR-296) (Table 2).
Internalization of islet-derived EVs and induction of
insulin mRNA expression within IECs
After labelling with the red fluorescent dye PKH26, we
observed a dose-dependent internalization of islet-derived EVs
into IECs (Figure 2A). EV internalization was already present
3 hrs after incubation reaching a peak at 12 hrs with a plateau at
24 hrs (Figure 2B). Experiments with blocking monoclonal
antibodies were then performed to define the role of specific
adhesion molecules expressed on EV surface in their internaliza-
tion. By GUAVA FACS analysis, we found that EV internaliza-
Figure 6. Representative western blot analysis and relative densitometric quantification of AKT, eNOS and ERK. Results are expressed
as ratio between phosphorylated (P-AKT, P-eNOS, P-ERK) and non-phosphorylated (AKT, eNOS, ERK) forms. Three different experiments were
performed and data are expressed as mean 6 SD. (*p,0.05 EVs at different time points vs. vehicle alone).
doi:10.1371/journal.pone.0102521.g006
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tion was significantly decreased in presence of a blocking antibody
directed to ICAM-1 (Figure 2C). In addition, the inhibition of
CD44 by incubation with HA significantly reduced EV internal-
ization (Figure 2C).
We then investigated the potential transfer of mRNAs from EVs
to target IECs. We selected as a marker insulin mRNA that was
detected in islet-derived EVs. RT-PCR analysis demonstrated that
IECs did not basally express insulin mRNA. However, the
incubation with EVs induced in IECs the expression of insulin
mRNA with a peak at 3 hrs and a subsequent decrease at 12–
24 hrs (Figure 2D). EV-induced increase of insulin mRNA in IECs
was not observed when EVs were pre-treated with RNase
(Figure 2D). To further investigate EV-mediated RNA transfer,
we analysed different miRNA expression in IECs treated with EVs
and actinomycin D. Actinomycin D was used to inhibit RNA
transcription in IECs in concomitance to EV stimulation. We
selected miR-375, miR-200c and miR-21 as representative
miRNAs since they were particularly enriched in islet-derived
EVs. We observed that miR-375, miR-200c and miR-21 transfer
was evident after 3 hrs of EV stimulation and subsequently
decreased after 6 hrs (Fig. 2E).
Anti-apoptotic and pro-angiogenic effects of EVs on IECs
As shown by BrdU assay, EVs induced a dose-dependent
proliferation of IECs cultured in serum-free medium (Figure 3A).
An inhibition of apoptosis of IEC after incubation with EVs was
detected by TUNEL assay (Figure 3B). The proliferative and anti-
apoptotic effect of EVs were significantly reduced when EVs were
pre-treated with RNase, with a blocking antibody directed to
ICAM-1 or with HA (Figure 3A–D). EVs also induced a significant
increase of IEC migration (Figure 3E). Moreover, EV induced a
significant increase of in vitro capillary-like structure formation
after 12–24 hr incubation (Figure 3F and G). The migratory and
pro-angiogenic activities of EVs on IECs were similar to
stimulation with endothelial growth factor enriched medium
(EndoGF medium). These effects were significantly reduced by
RNase pre-treatment of EVs (Figure 3E–G). Gene array analysis
revealed that EVs up-regulated IEC expression of several pro-
angiogenic molecules such as angiopoietin1, TIE-2, VEGFR1,
FGFR3, ephrinA3 and the endothelial transcription factor
HAND2 (Figure 4A). Furthermore, EVs reduced the expression
of anti-angiogenic factors including collagen fragments (endostatin
and tumstatin), the adhesive glycoprotein thrombospondin1 and
the tissue inhibitors of metalloproteinases TIMP1 and 2
(Figure 4B). These results were confirmed at protein level by
western blot analysis. After EV stimulation, IECs showed an
increased expression of several pro-angiogenic (angiopoietin1,
VEGF-alpha, VEGFR1, VEGFR2) and anti-apoptotic factors
(BCL-2) and the concomitant down-regulation of anti-angiogenic
(thrombospondin1) and pro-apoptotic molecules (BAD) (Figure 5).
In addition, EV stimulation induced the phosphorylation of
intracellular signal transduction factors such as AKT, eNOS and
ERK (Figure 6).
Discussion
We herein demonstrated that freshly purified human pancreatic
islets release biologically active EVs which may play a role in beta
cell-endothelium cross-talk. The presence of proteins such as
insulin, C-peptide and GLP1R and of high level of insulin mRNA
within islet-derived EVs suggests that beta cells represent the main
source of origin. Alpha cell and endothelial markers (such as
CD31, eNOS and glucagon) were less expressed at both protein
and mRNA level, suggesting that only a little amount of EVs did
not derive from beta-cells, reflecting the normal architecture of
cells within human islets. The internalization of EVs in IECs
induced the expression of islet specific proteins and RNAs and
reprogrammed IECs toward a pro-angiogenic and anti-apoptotic
phenotype.
The presence of an intensive signal cross-talk between
endothelium and endocrine cells inside pancreatic islets has been
previously described [1–3]. Indeed, several experimental and
human studies identified different factors able to mediate mutual
signals in the adult pancreas [3]. Among these factors, the most
studied was VEGF-A a pro-angiogenic growth factor secreted by
differentiated endocrine cells. VEGF-A is able not only to attract
endothelial cells and to induce angiogenesis, but also to stimulate
formation of endothelial fenestrations essential for glucose sensing
and interstitial flow. Moreover, other factors are known to
contribute to survival and integrity of blood vessels such as the
angiopietin-1 and the tyrosine-kinase Tie-2 ligand [22–24]. On the
other hand, endothelial cells present in islets contribute to the
production of extracellular matrix components involved in beta-
cell physiology. In particular, proteins such as collagen IV,
laminins and Connective Tissue Growth Factor are able to
enhance insulin secretion, beta cell differentiation and specifica-
tion of endocrine lineages. Moreover, HGF has been shown to
induce beta cell proliferation in embryonic and postnatal pancreas
[25–28]. It has been demonstrated that conditioned medium
derived from cultured rat islets exerts a pro-angiogenic effect on
islet-derived endothelial cells, confirming the presence of paracrine
mediators involved in beta cell- endothelial cell cross-talk [9].
A growing number of evidences suggest that EVs may act as a
new mechanism of cell-to-cell communication [10,11]. Several
studies described the involvement of EVs in diverse biologic
processes such as tumor progression or tissue regeneration [29–
33]. We have previously shown that EVs released from bone
marrow-derived endothelial progenitor cells can be internalized by
IECs and beta cells inhibiting apoptosis and promoting insulin
secretion and angiogenesis in an experimental model of human
islet xenotransplantation in SCID mice [14].
In the present study, EVs released by human pancreatic islets
were shown to express the typical exosomal marker CD63 and
different adhesion molecules such as alpha-6, beta-1 integrin,
CD44 and ICAM1. Experiments using blocking antibodies
demonstrated that ICAM-1 and CD44 are critical for EV
internalization in IECs and consequently for EV-associated
functional effects. EVs also shuttled typical beta cell marker such
as insulin and C-peptide proteins, and AGO-2, a molecule
required for miRNA-mediated silencing complex [34].
Several studies demonstrated that the biological effects of EVs
from different origin can be ascribed to the horizontal transfer of
genetic material ensuing in recipient cell reprogramming
[13,14,35,36]. The comparative analysis of miRNAs present
within islets and those present in secreted EVs demonstrate an
enrichment of certain miRNAs, suggesting that their compart-
mentalization within EVs is not a random process. Some of the
miRNAs present in islet-derived EVs are known to modulate
glucose homeostasis and to interfere with the typical complications
of diabetes including nephropathy [37]. Of interest, EVs also
carried a subclass of miRNAs called angiomiRs (miR-126, miR -
296, miR -130 and miR -27b) which are known to possess a pro-
angiogenic activity through the increased signaling of several
growth factors (VEGF, EGF, FGF, PDGF) in endothelial cells
[38]. Furthermore, RT-PCR array showed that islet-derived EVs
contain different mRNAs of specific genes involved in islet
physiology such as insulin, glucagon and PDX-1. Moreover,
EVs carried also mRNAs of specific genes involved in endothelial
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cell biology and angiogenesis such as eNOS and VEGFa. The
internalization of EVs in IECs was followed by the up-regulation
of pro-angiogenic genes (angiopoietin 1, chemokine ligand 1,
ephrin A3, FGFR3, VEGFR1, HAND 2, Jagged 1, Leptin,
midkine, Neurophillin 2 and Tie 2) and down-regulation of genes
involved in inhibition of angiogenesis (endostatin, tumstatin,
thrombospondin 1, TIMP 1 and TIMP 2). The pro-angiogenic
and anti-apoptotic effects of islet-derived EVs were confirmed at
protein level by western blot analysis. EV stimulation induced the
up-regulation of VEGFR 1, VEGFR 2, VEGF A, Angiopoietin 1,
BCL 2 and the increase of the ratios p-AKT/AKT, p-eNOS/
eNOS and p-ERK/ERK, pathways typically involved in endo-
thelial cell activation. By contrast, thrombospondin 1 and BAD
were down-regulated following EV stimulation. This resulted in an
enhanced proliferation, an increased resistance to apoptosis and an
in vitro angiogenic response of IECs. The relevance of mRNAs
and miRNAs shuttled by EVs was suggested by the significant
decrease of their biological effects on IECs when pre-treated with
RNase. The insulin mRNA, which was absent in untreated IECs,
was detectable at 3 and 6 hrs to decrease thereafter. RT-PCR
analysis showed that EV treatment with RNase abrogated the
expression of mRNA coding for insulin within IECs. In similar
way, also miRNA-375, miRNA-200c, miRNA-21 were transferred
by EVs in IECs at 3 hrs. These data suggest that islet-derived EVs
shuttle several miRNAs and mRNAs which can play a role in beta
cell-endothelium cross-talk.
In conclusion, human islets release biologically active EVs able
to shuttle beta cell specific proteins, mRNAs and miRNAs. The
incorporation of EVs in IECs is followed by a cell reprogramming
toward a pro-angiogenic and anti-apoptotic cell phenotype. These
results suggest a role of islet-derived EVs in the preservation of
endothelial integrity and function.
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